FTC (US Federal Trade Commission) approves AmeriPath sale, shareholders rebel:
This article was originally published in Clinica
The US Federal Trade Commission has given antitrust clearance to the acquisition of genomic and cancer diagnostic services group AmeriPath by buy-out firm Welsh Carson Anderson & Stowe. WCAS unit Amy Acquisition is offering $21.25 per share in cash and to assume $172m of debt. Shareholders with a combined stake of about 4.5% have filed a lawsuit against the firm's directors on the grounds that the price is too low and not in shareholders' interests. AmeriPath's share is currently trading at $21.60; it was selling for $16.45 immediately before the offer was made in December.